IAXO-102 manufacturers
- IAXO-102
-
- $89.00 / 1mg
-
2025-12-09
- CAS:1115270-63-7
- Min. Order:
- Purity: 98.17%
- Supply Ability: 10g
- IAXO-102
-
- $89.00 / 1mg
-
2025-12-09
- CAS:1115270-63-7
- Min. Order:
- Purity: 98.17%
- Supply Ability: 10g
|
| | IAXO-102 Basic information |
| Product Name: | IAXO-102 | | Synonyms: | IAXO-102;α-D-Glucopyranoside, methyl 6-amino-6-deoxy-2,3-di-O-tetradecyl-;Methyl 6-amino-6-deoxy-2,3-di-O-tetradecyl-α-D-glucopyranoside;IAXO102,IAXO 102,Toll-like Receptor (TLR),Inhibitor,IAXO-102,inhibit;IAXO-102 (CD14/TLR4 Antagonist) (synthetic);IAXO-102 ，S0002 | | CAS: | 1115270-63-7 | | MF: | C35H71NO5 | | MW: | 585.96 | | EINECS: | | | Product Categories: | | | Mol File: | 1115270-63-7.mol |  |
| | IAXO-102 Chemical Properties |
| Boiling point | 650.2±55.0 °C(Predicted) | | density | 0.96±0.1 g/cm3(Predicted) | | storage temp. | under inert gas (nitrogen or Argon) at 2–8 °C | | solubility | Ethanol : 50 mg/mL (85.33 mM; Need ultrasonic)|DMSO : 5 mg/mL (8.53 mM; Need ultrasonic) | | form | A solid | | pka | 13.00±0.70(Predicted) | | color | White to off-white |
| | IAXO-102 Usage And Synthesis |
| Uses | IAXO-102 is a TLR4 antagonist which negatively regulates TLR4 signalling. IAXO-102 inhibits MAPK and p65 NF-κB phosphorylation and expression of TLR4 dependent proinflammatory protein. IAXO-102 also prevents experimental abdominal aortic aneurysm development[1]. | | Biological Activity | IAXO-102 is a TLR4 antagonist targeting the MD-2 and CD14 co-receptors,which inhibits MAPK and p65 NF-κB phosphorylation and downregulates the expression of TLR4-dependent pro-inflammatory proteins. It inhibits the development of experimental abdominal aortic aneurysm (AAA). | | in vitro | IAXO-102 (1-10 μM, for 2 hours) inhibits MAPK and p65 NF-κB phosphorylation in human umbilical vein endothelial (HUVEC) cells.
IAXO-102 (10 μM, for 17 hours) suppresses LPS induced proinflammatory proteins MCP-1 and IL-8 production in HUVEC. Western Blot Analysis | Cell Line: | Human umbilical vein endothelial (HUVEC) cells | | Concentration: | 1-10 μM | | Incubation Time: | Pretreatment for 1 hour and then exposed to LPS (100 ng/mL) for additional 1 hour | | Result: | Significantly inhibited LPS- stimulated MAPK/p65nF-ΚB phosphorylation. | | | in vivo | IAXO-102 (3 mg/kg/day, sc for 28 days) significantly retards Angiotensin II induced increase in aortic diameter in mice. | Animal Model: < /td> | Six-monthold ApoE ?/? /C57Bl6 | | Dosage: | 3 mg/kg/day | | Administration: | SC for 28 days | | Result: | Significantly retarded Angiotensin II -induced increase in aortic diameter. | | | target | | Target | Value | TLR4
() | MAPK
() | NF-κB
() |
| | IC 50 | TLR4 | | References | [1] Huggins C, et al. A novel small molecule TLR4 antagonist (IAXO-102) negatively regulates non-hematopoietic toll like receptor 4 signalling and inhibits aortic aneurysms development. Atherosclerosis. 2015 Oct;242(2):563-70. DOI:10.1016/j.atherosclerosis.2015.08.010 |
| | IAXO-102 Preparation Products And Raw materials |
|